Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
| Website: | www.clovisoncology.com |
| Email: | bburkart@clovisoncology.com |
| Main Phone: | +1 303 625-5000 |
| Address: | 5500 Flatiron Parkway |
| Address 2: | Suite 100 |
| State: | CO |
| City / Town: | Boulder |
| Country: | USA |
| Postal Code: | 80301 |
| Exchange: | NGS |
| CEO: | Patrick J. Mahaffy |
| Employees: | 468 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Stagnant markets most of the week, while Mylan came under fire and Kobe launched a new pursuit.
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Shares of Clovis Oncology (CLVS) are trading higher on Friday after the company reported financial results from the fourth quarter of 2013 and discussed the development of its pipeline after
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
Shares for Clovis Oncology (CLVS) are currently in their second straight day of over 10 percent gains. Last Friday, the company’s stock gained 15.6 percent to close at $21.81, and Monday saw
The 2013 rally in the metals markets appears to have run its course. The metal markets are now flushing the weak traders out of their positions and, at least for the gold futures and copper
As the price of gas cruises past $4 a gallon, there remain significant concerns about the capacity of the economy to continue growing if gas prices continue to rise. However, with the rising
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
| Website: | www.clovisoncology.com |
| Email: | bburkart@clovisoncology.com |
| Main Phone: | +1 303 625-5000 |
| Address: | 5500 Flatiron Parkway |
| Address 2: | Suite 100 |
| State: | CO |
| City / Town: | Boulder |
| Country: | USA |
| Postal Code: | 80301 |
| Exchange: | NGS |
| CEO: | Patrick J. Mahaffy |
| Employees: | 468 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Stagnant markets most of the week, while Mylan came under fire and Kobe launched a new pursuit.
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Shares of Clovis Oncology (CLVS) are trading higher on Friday after the company reported financial results from the fourth quarter of 2013 and discussed the development of its pipeline after
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
Shares for Clovis Oncology (CLVS) are currently in their second straight day of over 10 percent gains. Last Friday, the company’s stock gained 15.6 percent to close at $21.81, and Monday saw
The 2013 rally in the metals markets appears to have run its course. The metal markets are now flushing the weak traders out of their positions and, at least for the gold futures and copper
As the price of gas cruises past $4 a gallon, there remain significant concerns about the capacity of the economy to continue growing if gas prices continue to rise. However, with the rising
| Last Price 3.22 | Change $ 0.01 | Change % 0.31 | Tick N/A |
| Bid 3.21 | Bid Size 2,400.00 | Ask 3.22 | Ask Size 600.00 |
| Open 3.23 | High 3.32 | Low 3.19 | Prev Close 3.21 |
| Last Trade | Volume 1 mi | 52 Wk Hi 32.05 | 52 Wk Low 3.01 |
| Market Cap 175.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 54,656,539.00 | EPS (TTM) -7.50 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 15 | 61 |
| Number of Buys | 7 | 24 |
| Number of Sells | 8 | 37 |
| Net Activity | -27459 | -429324 |
| Last 10 Buys | Shares |
|---|---|
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Erle T. Mast | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Edward J. McKinley | 1,000 |
| Paul H. Klingenstein | 1,000 |
| James C. Blair | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Thorlef Spickschen | 1,000 |
| Thorlef Spickschen | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 97 | 97 | 97 | 97 |
| Low Target Price Estimate | 72 | 72 | 72 | 72 |
| Mean Target Price Estimate | 84.14 | 84.14 | 84.14 | 84.14 |
| Standard Deviation | 9.08 | 9.08 | 9.08 | 9.08 |
| Date of Most Recent Estimate | 06/05/18 | 05/09/18 | 05/09/18 | 06/05/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-01 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-01 |
| DEFA14A | Additional proxy soliciting materials - definitive | 2 | 2018-05-31 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-23 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2018-05-09 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 8 |
| Moderate Buy | 1 | 1 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.56 | 1.5 | 1.5 | 1.46 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait